-
Mashup Score: 0Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data - 3 month(s) ago
A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Stopping Tirzepatide Led to Weight Gain, Trial Shows - 3 month(s) ago
But sustained treatment kept the pounds off
Source: www.medpagetoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
Many of these medications are often not covered by insurance either.
Source: connecticut.news12.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 3
Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose and body weight in people with type 2 diabetes. The cardiovascular (CV) s…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison - 8 month(s) ago
Aim To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Materials and Methods Using SURMOUNT-1 and STEP 1 trial data, mean percentag…
Categories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1SURMOUNT-2 Study Finds Individuals with Type 2 Diabetes and Obesity Lost an Average of 15% of Their Body Weight when Taking Tirzepatide | ADA - 9 month(s) ago
American Diabetes Association Symposium Demonstrates Benefits of Once Weekly Drug for Weight Loss and Glycemic Control Today, findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced, demonstrating more weight loss in individuals with diabetes than any other medication to date. The results were presented at the 83rd Scientific Sessions…
Source: diabetes.orgCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0'Staggering' Weight Loss With Tirzepatide - 10 month(s) ago
Over 60% of participants achieved the weight-reduction target of 20% or higher and had improved body composition in a phase 3 trial of tirzepatide in overweight/obesity.
Source: MedscapeCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes - 10 month(s) ago
OBJECTIVE. To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight l
Source: American Diabetes AssociationCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Adults with obesity lose nearly 15% of body weight with glucagon/GLP-1 receptor agonist - 11 month(s) ago
A novel glucagon/GLP-1 receptor agonist conferred nearly 15% weight loss at 46 weeks among people with overweight or obesity without type 2 diabetes, according to an industry press release. In a phase 2 clinical trial, participants with overweight or obesity and no diagnosis of type 2 diabetes were randomly assigned to subcutaneous BI 456906 (Boehringer Ingelheim and Zealand Pharma) or placebo
Source: www.healio.comCategories: Healthcare Professionals, Latest HeadlinesTweet
A network meta-analysis of semaglutide and tirzepatide trials suggests #tirzepatide could provide more efficacious reductions in HbA1c and superior reductions in body weight. https://t.co/fzodVtse1P